| 期刊全称 | Frontiers in Bioengineering and Biotechnology | ||||||||||||||||||||||||||||||||||||
| 期刊缩写 | Front. Bioeng. Biotechnol. | ||||||||||||||||||||||||||||||||||||
|
涉及主题
（科研通AI识别） |
|||||||||||||||||||||||||||||||||||||
| 期刊介绍 | The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application. | ||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||
| 期刊ISSN | print: 2296-4185 | ||||||||||||||||||||||||||||||||||||
| 2023最新影响因子 (2024年6月20日公布) 与上一年的差值 |
4.3↓ 1.4 | ||||||||||||||||||||||||||||||||||||
| 历年影响因子 |
|
||||||||||||||||||||||||||||||||||||
| 历年发表/被引量 （科研通AI通过大数据分析） |
|
||||||||||||||||||||||||||||||||||||
| h-index（2021） | 暂无h-index数据 | ||||||||||||||||||||||||||||||||||||
| 自引率 | 4.70% | ||||||||||||||||||||||||||||||||||||
| 涉及的研究领域 | Chemical Engineering-Bioengineering | ||||||||||||||||||||||||||||||||||||
| WOS期刊分区 （2024年6月20日公布） |
JCR学科分类
JCI学科分类
|
||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2023年12月升级版） |
|
||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2022年12月升级版） |
|
||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2021年12月基础版） |
|
||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2021年12月升级版） |
|
||||||||||||||||||||||||||||||||||||
| 中科院《国际期刊预警名单（试行）》名单 |
2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 |
||||||||||||||||||||||||||||||||||||
| 期刊主页 |
（系统检测到多个链接，仅供参考，如有错误，请通过页面底部反馈） |
||||||||||||||||||||||||||||||||||||
| 投稿网址 | https://www.frontiersin.org/submission/SubmissionHome.aspx?domainId=1&fieldId=7&specialtyId=0&entityType=1&entityId=452 | ||||||||||||||||||||||||||||||||||||
| 编辑部地址 | AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, SWITZERLAND, CH-1015 | ||||||||||||||||||||||||||||||||||||
| 出版商 | Frontiers Media S.A. | ||||||||||||||||||||||||||||||||||||
| 出版国家（地区） | Switzerland | ||||||||||||||||||||||||||||||||||||
| 出版语言 | English | ||||||||||||||||||||||||||||||||||||
| 出版周期 | |||||||||||||||||||||||||||||||||||||
| 每年出版文章数 | 1345 | ||||||||||||||||||||||||||||||||||||
| Gold OA文章占比 | 99.42% | ||||||||||||||||||||||||||||||||||||
| 原创研究文献占比 （排除综述） |
75.84% | ||||||||||||||||||||||||||||||||||||
| SCI收录类型 |
Science Citation Index Expanded (SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) |
||||||||||||||||||||||||||||||||||||
| PubMed链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2296-4185%5BISSN%5D | ||||||||||||||||||||||||||||||||||||
| 平均审稿周期 | 网友分享经验： 12 Weeks |
||||||||||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： |
||||||||||||||||||||||||||||||||||||
| 相关链接 |
您可以在上述网站查看该期刊的网友互动，及期刊影响力的其它指标。
|
||||||||||||||||||||||||||||||||||||
皖公网安备34019202002308
